<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102463</url>
  </required_header>
  <id_info>
    <org_study_id>FHI-3</org_study_id>
    <nct_id>NCT03102463</nct_id>
  </id_info>
  <brief_title>The Role of Milk Derived Peptides on Glycaemic Control</brief_title>
  <official_title>The Role of Milk Derived Peptides on Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Enterprise Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to ascertain the potential of novel milk derived hydrolysates to improve
      glycaemic control to promote metabolic health. A comprehensive characterisation of the
      metabolic response to these milk derived hydrolysates will ascertain the effect of the
      hydrolysates in terms of insulin sensitivity. These hydrolysates have been shown to improve
      insulin resistance in cell and animal models. Therefore the investigators aim is to test
      their efficacy in overweight, insulin resistant individuals at risk of developing type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent figures estimate 60% of Irish adults are overweight or obese. As obesity is associated
      with the development of insulin resistance, which precedes type 2 diabetes development by
      decades, novel food based solutions are required to improve glycaemic control and attenuate
      insulin resistance.

      In the current study insulin resistant individuals will undergo 4 study visits, 1 screening
      visit and 3 subsequent visits. At each of the 3 visits they will receive an oral lipid load
      consisting of 100mL soya bean oil, followed by either a water control; the hydrolysate being
      tested or the parent protein from which the hydrolysate was derived. After which they will
      undergo a 4 hour hyperinsulinemic-euglycaemic clamp at each visit to assess their insulin
      sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Disposal Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>M-value (mg/kg/min) /Glucose disposal rate will be used to measure of insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of glycaemic control</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glucose (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of glycaemic control</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin (mU/L)inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>Non-esterified fatty acids (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglycerides (mmol/L) and other related lipid markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>High sensitivity C reactive protein (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>C-peptide (ng/mL) and other related</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Water Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk derived hydrolysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Parent Protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water Control</intervention_name>
    <description>120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp</description>
    <arm_group_label>Water Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Milk derived hydrolysate</intervention_name>
    <description>Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp</description>
    <arm_group_label>Milk derived hydrolysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parent Protein</intervention_name>
    <description>Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp</description>
    <arm_group_label>Parent Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lipid Load</intervention_name>
    <description>100mL oral lipid load</description>
    <arm_group_label>Water Control</arm_group_label>
    <arm_group_label>Milk derived hydrolysate</arm_group_label>
    <arm_group_label>Parent Protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 65 years

          -  BMI &gt; 26 kg/m2

          -  Prepared to maintain a constant body weight for the duration of the study

          -  Free of any chronic or infectious disease

          -  Not taking any medication for the regulation of blood sugars

          -  Diet controlled type 2 diabetes

          -  Free of any milk allergies or lactose intolerance

          -  Without anaemia

        Exclusion Criteria:

          -  &lt;18 or &gt;65 years

          -  Diabetes (pharmacologically treated) or other endocrine disorders.

          -  Chronic inflammatory conditions.

          -  Kidney or liver dysfunction.

          -  Anaemia (Haemoglobin &lt;12g/dl men, &lt; 11g/dl women).

          -  Taking any medication for the regulation of blood sugars.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen M Roche, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Dublin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Dublin</investigator_affiliation>
    <investigator_full_name>Prof Helen M Roche</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Milk derived hydrolysate</keyword>
  <keyword>Hyperinsulinemic-euglycaemic clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

